Immunization Program

TO: Health Care Providers
FROM: Mick Bolduc
Vaccine Coordinator-Connecticut Vaccine Program (CVP)
DATE: May 23, 2016
SUBJECT: DTaP/IPV/Hib (Pentacel®) vaccine supply update

The primary purpose of this communication is to update you on the supply of Pentacel® vaccine.

**DTaP/IPV/Hib (Pentacel®) supply**
This memo is a follow up to the information we shared with you in late November about the Pentacel Vaccine Delay. At the time the delay was announced, Sanofi Pasteur projected that allocations of Pentacel were anticipated to last through the first half of 2016. We have now received an update from Sanofi Pasteur that, while progress has been made regarding this vaccine delay, there is a need to extend allocations into the second half of 2016.

A final resolution date for the vaccine delay is not yet available, but we will share updates with you as we receive them. Attached is a letter that Sanofi will be sending to providers about the delay.

Based on this information, the CVP will be continuing to allocate Pentacel orders at the same levels you have been receiving.

As always, if you have any questions, please feel free to contact me at (860) 509-7940.
May 2016

Dear Health Care Provider:

The purpose of this letter is to provide you with an update on Pentacel® (Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed, Inactivated Poliovirus and Haemophilus b Conjugate [Tetanus Toxoid Conjugate] Vaccine) supply. In December of 2015, we informed all customers of a manufacturing delay with Pentacel vaccine, resulting in the need to implement customer level allocations to responsibly manage supply. These allocations were anticipated to last through the first half of 2016. Although progress has been made, we will be extending the current allocations into the second half of 2016. We will share more information as it becomes available.

We understand the difficulty of managing your office’s immunization schedule with allocated supply, and regret the need to extend current allocations. We will continue to make our separately administered vaccines available so that your patients may continue to receive their required vaccinations.

Should you have any questions or require additional information, please contact your sales representative, or call our customer account representatives at 1-800-VACCINE (1-800-822-2463).

Sincerely,

Matthew Wilcox
Vice President Marketing, US

MKT31017